Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesCorcept Therapeutics Incorporated

Corcept Therapeutics Incorporated

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
74.55 USD 0.02 ( 0.03%)
Last update at 2026-11-12T15:46:00Z
VOLUME
123243
Market Cap
11979.46M
P/E
251.86

Momentum Score

…

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
72.23
Low
74.62
High
52 Week Price Range
28.66
Low
126.38
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Corcept Therapeutics develops drugs that antagonize the glucocorticoid receptor to treat endocrine disorders and certain oncology indications; its approved product, Korlym (mifepristone), treats endogenous Cushing's syndrome and the company is advancing relacorilant and other pipeline candidates. Long-term growth may be supported by ongoing Korlym revenues, potential regulatory approvals and label expansions for relacorilant, and clinical readouts that could broaden oncology use.
Principal risks include clinical or regulatory failures in late-stage programs, commercial concentration on a small product portfolio, pricing and reimbursement pressure, and intellectual property or litigation challenges.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
74.53
Dividend Yield
-
Revenue TTM
830.81M
Revenue Per Share
7.97
Gross Profit TTM
816.73M
Debt / Equity
0.01
ROE
8.23%
Net Debt
-114.39M
ROCE
9.91%
Diluted EPS TTM
0.44

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 66.46M 161.49M 124.56M 116.19M 125.01M
Net income 99.65M 139.73M 106.14M 101.42M 112.51M
Selling general administrative 448.73M 280.32M 184.26M 152.85M 122.36M
Gross profit 748.43M 664.16M 475.89M 396.47M 360.70M
Reconciled depreciation 1.89M 1.34M 2.36M 2.97M 3.07M
Ebit 66.46M 136.95M 107.28M 109.67M 121.41M
Ebitda 68.35M 138.29M 108.32M 112.63M 124.48M
Depreciation and amortization 1.89M 1.34M 1.04M 2.97M 3.07M
Non operating income net other - - - - 0.53M
Operating income 44.80M 136.95M 107.28M 112.63M 124.48M
Other operating expenses 716.61M 538.09M 375.09M 289.22M 241.50M
Interest expense - - - 3.56M 3.60M
Tax provision -33.19M 20.28M 18.42M 14.77M 12.49M
Interest income 21.67M 24.54M 17.27M 3.56M 0.53M
Net interest income 21.67M 24.54M 17.27M 3.56M 0.53M
Income tax expense -33.19M 20.28M 18.42M 14.77M 12.49M
Total revenue 761.41M 675.04M 482.38M 401.86M 365.98M
Total operating expenses 703.63M 527.21M 368.61M 283.84M 236.22M
Cost of revenue 12.98M 10.88M 6.48M 5.38M 5.28M
Total other income expense net 21.67M 24.54M 17.27M 3.56M 0.53M
Net income from continuing ops 99.65M 141.21M 106.14M 101.42M 112.51M
Net income applicable to common shares - - - 101.29M 112.51M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 836.65M 840.55M 621.52M 583.43M 423.76M
Other current assets 40.66M 17.78M 27.56M 16.42M 10.31M
Total liab 188.85M 160.96M 114.81M 81.59M 47.95M
Total stockholder equity 647.80M 679.59M 506.70M 501.84M 375.81M
Other current liab 109.38M 124.38M 0.65M 68.47M -0.53M
Common stock 0.14M 0.14M 0.13M 0.13M 0.13M
Capital stock 0.14M 0.14M 0.13M 0.13M 0.13M
Retained earnings 643.39M 543.74M 402.53M 296.39M 194.97M
Other liab - - - 9.10M 0.41M
Other assets - - - 77.45M 43.50M
Cash 120.50M 127.67M 135.55M 436.62M 335.81M
Total current liabilities 166.09M 140.77M 104.50M 81.59M 6.91M
Current deferred revenue - - 86.30M - -
Net debt -114.39M -120.73M -135.40M -435.48M -335.29M
Short term debt 1.08M 0.83M 0.15M 1.14M 0.53M
Short long term debt total 6.11M 6.94M 0.15M 1.14M 0.53M
Other stockholder equity 2.01M 135.94M 103.44M 206.19M 180.94M
Property plant equipment - - - 1.78M 1.00M
Total current assets 485.46M 471.60M 458.64M 498.71M 381.39M
Long term investments 160.27M 219.83M 57.18M 4.95M 112.28M
Net tangible assets - - - 501.84M 375.81M
Short term investments 251.66M 255.67M 232.67M 365.34M 145.92M
Net receivables 59.79M 58.08M 55.12M 45.06M 27.62M
Inventory 12.87M 12.41M 7.73M 17.03M 17.95M
Accounts payable 40.44M 15.38M 17.40M 11.98M 6.91M
Accumulated other comprehensive income 2.26M -0.22M 0.61M -0.87M -0.23M
Common stock total equity - - - - 0.13M
Retained earnings total equity - - - - 194.97M
Non currrent assets other 176.52M 10.19M 14.79M 17.17M 14.40M
Non current assets total 351.19M 368.95M 162.88M 84.72M 42.37M
Capital lease obligations 6.11M 6.94M 0.15M 1.14M 0.53M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 69.97M -177.60M 56.57M -114.33M 136.59M
Change to liabilities - - - 4.76M 1.63M
Total cashflows from investing activities 69.76M -177.60M 90.91M -114.33M 136.13M
Total cash from financing activities -220.37M -28.35M -148.72M -17.28M -302.59M
Change to operating activities - - - -5.20M 1.51M
Net income 98.17M 141.21M 106.14M 101.42M 112.51M
Change in cash -7.17M -7.89M 69.22M -11.29M 1.43M
Begin period cash flow 127.67M 135.55M 66.33M 77.62M 76.19M
End period cash flow 120.50M 127.67M 135.55M 66.33M 77.62M
Total cash from operating activities 142.00M 198.07M 127.04M 120.32M 167.89M
Depreciation 1.89M 1.34M 2.36M 2.97M 3.07M
Change to inventory -7.48M 0.30M 1.26M 1.20M 3.44M
Change to account receivables -5.81M 1.15M -10.07M -3.43M -1.43M
Sale purchase of stock -245.86M -15.66M -145.43M 0.00M -295.99M
Other cashflows from financing activities 25.49M -22.30M -3.29M -21.66M -6.61M
Change to netincome - - - 9.92M 47.29M
Capital expenditures 0.21M 2.17M 0.14M 0.41M 0.47M
Change receivables - - - - -1.43M
Cash flows other operating - - - - 3.37M
Cash and cash equivalents changes - - - - 1.43M
Change in working capital -27.57M 45.30M 8.22M 6.02M -0.06M
Stock based compensation 84.50M 61.35M 48.94M 42.44M 42.93M
Other non cash items -15.00M -10.94M -9.13M 1.38M 5.09M
Free cash flow 141.78M 195.90M 126.90M 119.91M 167.42M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CORT
Corcept Therapeutics Incorporated		 0.02
0.03%		 74.55 251.86 18.38 14.42 17.13 14.19 1335.84
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

101 Redwood Shores Parkway, Redwood City, CA, United States, 94065

650 327 3270

https://www.corcept.com

730

Name Title Year Born
Dr. Joseph K. Belanoff M.D. Co-Founder, Pres, CEO & Director 1957
Mr. Atabak Mokari CFO & Treasurer 1977
Dr. Hazel Hunt Ph.D. Chief Scientific Officer 1960
Mr. Sean Maduck Pres of Corcept Endocrinology 1977
Mr. Gary Charles Robb Chief Bus. Officer & Sec. 1963
Mr. Joseph Douglas Lyon Chief Accounting Officer 1979
Ms. Amy Flood Chief HR & Communications Officer NA
Dr. William Guyer Pharm.D. Chief Devel. Officer 1968
Dr. Joseph K. Belanoff M.D. Co-Founder, President, CEO & Director 1957
Mr. Sean Maduck President of Endocrinology 1977

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…